D.C. Circuit Rejects Mylan's Bid To Make Generic Duragesic

Law360, New York (December 7, 2004, 12:00 AM EST) -- A U.S. appeals court in Washington, D.C. has rejected Mylan Laboratories' bid to market a generic version of Johnson & Johnson's Duragesic pain-relief skin patch.

The United States Court of Appeals for the District of Columbia Circuit upheld a June decision by the Food and Drug Administration and affirmed another court ruling that allowed Johnson & Johnson to retain exclusive rights to Duragesic until January as a reward for testing the effects of the drug on children.

The D.C. Circuit held that the FDA did not...
To view the full article, register now.

Law360 UK

UK Financial Services

Read Our Latest UK Legal News & Analysis

Financial Services Law360 UK and Insurance Law360 UK provide breaking news and in-depth analysis on U.K. and European Union regulation, enforcement, legislation, and litigation involving banks, investment firms, insurers, and more.